Ways to Engage

About Stanford Center for Clinical Research

Stanford Center for Clinical Research (SCCR) is a leading ARO and an epicenter for clinical research operations at Stanford University. We offer full research capabilities: from study design to publication.

Our rigorous scientific investigations are supported by high-quality and efficient operational processes undertaken by well-trained clinical research staff. Our team has expertise in diverse therapeutic areas and modalities such as drugs, devices, digital health, and behavioral interventions.

SCCR’s dedicated team optimizes project success and sponsor satisfaction by leveraging the synergies from co-leadership with talented operations staff and experienced faculty.

SCCR by the Numbers Since 2014

200+

Staff, Faculty and Data Science Partners

28

University Partnerships

13

External Academic Partners

27

Industry & Federal Partners

250+

Research Projects

500k

Participants
Enrolled

12

Investigational New Drug Applications

115k

Endpoints Adjudicated

280+

Publications

260+

Education Programs Completed

Thank you to our sponsors and partners for their ongoing support.

SCCR Publications

The Apple Heart Study

LIMIT 

  • Multi-center prospective phase II randomized, controlled trial looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s.
  • Enrollment target: 480
  • Sponsor: NIH

 
ARREST 

  • Multi-center double-blind phase III randomized clinical trial to test if treatment with inhaled medications lower the risk of acute respiratory failure in patients with pneumonia and hypoxia
  • Enrollment target: 600
  • Sponsor: NIH/NHLBI
ARREST Pneumonia

  • Levitt JE, Festic E, Desai M, Hedlin H, Mahaffey KW, Rogers AJ, Gajic O, Matthay MA; ARREST Pneumonia Clinical Trial Investigators. The ARREST Pneumonia Clinical Trial. Rationale and Design. Ann Am Thorac Soc. 2021 Apr;18(4):698-708. doi: 10.1513/AnnalsATS.202009-1115SD. PMID: 33493423; PMCID: PMC8008996.

Clinical Events Classification
DETAP
Project Baseline Health Study

 

MILVEXIAN

 

SMARTAdhere
Smartguide
Vorapaxar
The Apple Heart Study

 

 

  • Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, Hung G, Lee J, Kowey P, Talati N, Nag D, Gummidipundi SE, Beatty A, Hills MT, Desai S, Granger CB, Desai M, Turakhia MP; Apple Heart Study Investigators. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019 Nov 14;381(20):1909-1917. doi: 10.1056/NEJMoa1901183. PMID: 31722151; PMCID: PMC8112605.

 

Key SCCR Programs

leave this here do not delete

LIMIT 

  • Multi-center prospective phase II randomized, controlled trial looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s.
  • Enrollment target: 480
  • Sponsor: NIH

 
ARREST 

  • Multi-center double-blind phase III randomized clinical trial to test if treatment with inhaled medications lower the risk of acute respiratory failure in patients with pneumonia and hypoxia
  • Enrollment target: 600
  • Sponsor: NIH/NHLBI
NIH/NHLBI Studies

LIMIT 

  • Multi-center prospective phase II randomized, controlled trial looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s.
  • Enrollment target: 480
  • Sponsor: NIH

 
ARREST 

  • Multi-center double-blind phase III randomized clinical trial to test if treatment with inhaled medications lower the risk of acute respiratory failure in patients with pneumonia and hypoxia
  • Enrollment target: 600
  • Sponsor: NIH/NHLBI
Multi-center Industry studies

 Librexia (Open to enrollment)

  • Multi-center trial Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
  • Enrollment: up to XXX
  • Sponsor: Janssen Research & Development, LLC

 
Project Baseline Health Study 

Click here for more information on Project Baseline.

  • Multi-center observational trial characterizing the transitions between stages of health and disease, which could provide opportunities for the development of interventions, therapeutics and diagnostics
  • Enrollment: 10,000
  • Sponsor: Verily Life Sciences

 
CSL300 (Open to enrollment)

  • Multi-center trial Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis
  • Enrollment: up to 2310
  • Sponsor: CSL Behring
Decentralized trials

Apple Heart Study

  • Decentralized single-arm clinical trial for evaluation and validation of Apple Watch for detection of atrial fibrillation
  • Enrollment: 419927
  • Sponsor: Apple Inc

Project Baseline Health Study

  • Decentralized observational trial characterizing the transitions between stages of health and disease, which could provide opportunities for the development of interventions, therapeutics and diagnostics
  • Enrollment: 10,000

 DeTAP 

  • Decentralized trial in atrial fibrillation patients aimed to validate the feasibility, acceptability and best practices of coordinating/integrating several individual digital health technologies to achieve execution of high compliance, cost-efficient, and scientifically sound clinical trials
  • Enrollment: 102
Clinical Endpoint Classification

Click here for more information.

Quality Assurance, Monitoring & Regulatory Affairs

Click here for more information.

Education & Training

Click here for more information. 

Our Team

Our Core Values and Principles